Mens Birth Control Options Could Be Expanded via a Non-Hormonal Pill

Mens Birth Control Options Could Be Expanded via a Non-Hormonal Pill ...

Women have many choices for birth control, from tablets to intrauterine devices, and partly as a result, they are burdened most of the process of preventing pregnancy. However, mens birth control options and, therefore, roles might soon expand. A non-hormonal male contraceptive that effectively prevents pregnancy in mice, without obvious side effects.

At the spring meeting of the American Chemical Society (ACS) the researchers will present their findings today. ACS Spring 2022 is a hybrid meeting scheduled for virtually and in person March 20-24, with on-demand access available from March 21 to April 8. The meeting includes more than 12,000 presentations on a wide range of scientific topics.

Men need a fast-paced but effective contraceptive, similar to the birth control tablet for women. Despite the fact that condoms are single-use only and susceptible to failure. In contrast, vasectomy is considered a permanent form of male sterilization. However, the reversal surgery is expensive and not always successful.

Scientists have been working on an effective male oral contraceptive for decades, but there are still no approved medications on the market, according to Md Abdullah Al Noman, who will present the work at the meeting. Most compounds currently undergoing clinical trials target the male sex hormone testosterone, which might result in weight gain, depression, and increased low-density lipoprotein (LDL) cholesterol levels. Noman, a graduate student at the University of Minnesota, wants to develop a non-hormonal male contra

Researchers used a protein called the retinoic acid receptor alpha (RAR-), which is a protein called retinoic acid, a form of vitamin A that plays significant roles in cell growth, differentiation, and embryonic development. Knocking out the RAR- gene in male mice makes them sterile, without any obvious side effects. Other researchers have developed an oral compound that inhibits all three members of the RAR family (RAR-, -, and -) and causes reversible

So, the researchers studied crystal structures of RAR- and - bound to retinoic acid, identifying structural differences in the ways the three receptors bind to their common ligand. Using this information, they developed and synthesized approximately 100 compounds and evaluated their ability to selectively inhibit RAR- in cells. YCT529 significantly reduced sperm counts and was 99% effective in preventing pregnancy, without any adverse effects. The mice may father pups once more 4-6 weeks after they received the compound.

According to Georg, YCT529 will begin testing in human clinical trials in the third or fourth quarter of 2022. Because it can be difficult to predict if a compound that looks good in animal studies will also pan out in human clinical trials, she said. The researchers are both altering the existing compound and testing new structural scaffolds. They hope that their efforts will finally bring the elusive oral male contraceptive to fruition.

The researchers have given thanks to the National Institutes of Health and the Male Contraceptive Initiative. Georg is a consultant for YourChoice Therapeutics.

You may also like: